Nunzia Pharmaceutical Corporation is a pharmaceutical company. The Company focuses on development and delivery of pharmaceutical and nutraceutical-based therapies for the behavioral symptoms of Autistic Spectrum of Disorders (ASDs) and related conditions, such as Fragile X syndrome, as well as common anxiety-based disorders. The Company has developed NUNZIA, which is a combination of 16 vitamins, minerals and herbs which directly focuses and targets the hippocampus area of the brain, where all anxiety-based disorders originate.

Employees

Sector

Pharmaceuticals

More about the company

Market Closed - OTC Markets 09:34:37 2025-12-24 EST			5-day change	1st Jan Change
0.000100 ^USD	-.--%		-.--%	-

22-11-14	Nunzia Pharmaceutical Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-10-03	Nunzia Pharmaceutical Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI

Market Cap	34.76M 30.31M 28.62M 25.99M 48.7M 3.34B 48.9M 343M 132M 1.7B 131M 128M 5.46B	P/E 2020	-94.8x	P/E 2021	-2.54x
Enterprise Value	34.86M 30.4M 28.7M 26.06M 48.83M 3.34B 49.04M 344M 133M 1.7B 131M 128M 5.47B	EV / Sales 2020	-	EV / Sales 2021	-
Free-Float	18.04%	Yield 2020 *	-	Yield 2021	-

22-11-14	Nunzia Pharmaceutical Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-10-03	Nunzia Pharmaceutical Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
22-05-23	Nunzia Pharmaceutical Company Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
22-04-15	Nunzia Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	CI
22-04-14	Nunzia Pharmaceutical Company Auditor Raises 'Going Concern' Doubt	CI
22-03-28	Nunzia Pharmaceutical Company Auditor Raises 'Going Concern' Doubt	CI
21-11-10	Nunzia Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
21-09-16	Nunzia Pharmaceutical Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	CI
21-08-16	Nunzia Pharmaceutical Corporation Announces Offering of Patented Blood Warmer Through Medical Supply Division	CI
21-08-06	Nunzia Pharmaceutical Corporation Signs A Licensing Agreement with Michael Mitsunaga	CI
21-06-24	Global WholeHealth Partners Corporation acquired distribution and selling rights of Moderna Vaccine of Nunzia Pharmaceutical Corporation.	CI
21-06-16	Global Wholehealth Partners Corporation Partners with Nunzia Pharmaceutical Inc. to Distribute and Sell the Pfizer-BioNTech COVID-19 Vaccine	CI
21-06-10	Global Wholehealth Partners Corporation Grants the Rights from Nunzia Pharmaceutical Inc. to Distribute and Sell the Johnson & Johnson Covid-19 Vaccine	CI

22-11-14	NUNZIA PHARMACEUTICAL CO Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
22-10-03	NUNZIA PHARMACEUTICAL CO Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
22-05-23	NUNZIA PHARMACEUTICAL CO Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
22-04-15	NUNZIA PHARMACEUTICAL CO MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
22-03-29	NUNZIA PHARMACEUTICAL CO Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q/A)	AQ

Nunzia Pharmaceutical Company Stock

Stocks

NUNZ

US67097W1027

Pharmaceuticals

Valuation: Nunzia Pharmaceutical Company

Chart: Nunzia Pharmaceutical Company

Latest news: Nunzia Pharmaceutical Company

Press Releases: Nunzia Pharmaceutical Company

Price Extremes

Managers and Directors: Nunzia Pharmaceutical Company

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Sara Gonzales CEO	Chief Executive Officer	53	-
Michael Mitsunaga CEO	Chief Executive Officer	70	2008-12-31
Shujie Cui CTO	Chief Tech/Sci/R&D Officer	64	2019-12-04

Director	Title	Age	Since
Michael Mitsunaga BRD	Director/Board Member	70	2008-12-31
Sara Gonzales BRD	Director/Board Member	53	-
Shujie Cui BRD	Director/Board Member	64	2019-12-04

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NUNZIA PHARMACEUTICAL COMPANY	-.--%	-.--%	-.--%	-96.67%	43.45K
ELI LILLY AND COMPANY	+0.04%	+3.34%	+51.12%	+101.82%	1,028B
JOHNSON & JOHNSON	-0.09%	+1.66%	+55.02%	+66.18%	651B
ABBVIE INC.	-0.02%	+2.66%	+18.91%	+71.47%	466B
ROCHE HOLDING AG	-1.22%	+3.66%	+36.44%	+38.32%	346B
NOVARTIS AG	-0.79%	+2.73%	+19.03%	+25.08%	266B
ASTRAZENECA PLC	+0.58%	+6.76%	+11.13%	+16.52%	259B
AMGEN INC.	+1.55%	+2.20%	+39.81%	+46.55%	208B
NOVO NORDISK A/S	+0.79%	+1.84%	-28.27%	-56.71%	191B
GILEAD SCIENCES, INC.	-0.52%	+4.45%	+32.12%	+98.51%	186B
Average	+0.18%	+2.93%	+23.53%	+31.11%	360.17B
Weighted average by Cap.	+0.23%	+3.09%	+35.15%	+61.76%

	2020	2021
Net sales	-	-
Net income	-9.02M -7.86M -7.42M -6.74M -12.63M -865M -12.68M -88.93M -34.32M -440M -33.87M -33.12M -1.42B	-78.06M -68.07M -64.27M -58.37M -109M -7.49B -110M -770M -297M -3.81B -293M -287M -12.25B
Net Debt	-	97.31K 84.86K 80.12K 72.76K 136K 9.34M 137K 960K 370K 4.75M 366K 357K 15.28M

Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		3
10 years	0		331.65